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Abstract Despite recent advances in radiotherapy and
chemotherapy, survival rates for squamous cell carcinoma
of the head and neck (SCCHN) have remained poor. The
focus of SCCHN therapy has more recently shifted to the
molecular level, particularly the epidermal growth factor
receptor (EGFR/ErbB) pathway. Several agents that target
the EGFR pathway, including monoclonal antibodies and
tyrosine kinase inhibitors, are under investigation for
SCCHN. Searches of PubMed and results of key oncology
congresses were performed to identify relevant articles
and abstracts. The EGFR-targeted monoclonal antibody
cetuximab is approved for the treatment of locally advanced
SCCHN in combination with radiotherapy, for first-line
treatment of recurrent or metastatic SCCHN in combina-
tion with platinum-based chemotherapy and 5-fluorouracil,
and for recurrent or metastatic SCCHN following pro-
gression with platinum-based chemotherapy. Other inves-
tigational EGFR-targeted monoclonal antibodies (e.g.,
panitumumab, nimotuzumab, zalutumumab) are in clinical
development for SCCHN. Inhibition of the tyrosine kinase
domain of EGFR has also been explored as a therapeutic
approach in SCCHN using small-molecule reversible
inhibitors, such as gefitinib and erlotinib. However, a key
challenge in SCCHN is the development of resistance, and
strategies are being pursued to delay or overcome resis-
tance to EGFR-targeted agents. These strategies include
development of agents that inhibit multiple ErbB receptors
simultaneously (e.g., lapatinib) or that bind multiple ErbB
family receptors irreversibly (e.g., afatinib, PF-00299804)
and investigation of combinations of agents that target
multiple pathways implicated in the pathogenesis of
SCCHN. Ongoing large clinical trials are evaluating these
emerging agents and combinations for the treatment of
SCCHN.
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Introduction
Head and neck cancer comprises a spectrum of malignan-
cies that develop primarily within the oral cavity, pharynx,
and larynx. In 2010, there were an estimated 49,260 new
cases of head and neck cancers in the United States, and
11,480 patients died from the disease [1]. Squamous cell
carcinoma of the head and neck (SCCHN) is the principal
histologic subtype of this disease, accounting for[90% of
all cases [2]. Management of early-stage SCCHN often
involves surgery or radiotherapy, which may be curative.
Locally advanced disease is generally treated with a
combination of surgery, chemoradiotherapy, and/or tar-
geted therapy, while the standard approach for treatment of
recurrent or metastatic SCCHN is platinum-based chemo-
therapy [3, 4].
The focus of SCCHN therapy has shifted to the
molecular level, particularly the epidermal growth factor
receptor (EGFR/ErbB1/HER1) pathway (Fig. 1) [5]. EGFR
protein expression is detected in [90% of all SCCHN
tumors [6–8]. In addition, high levels of EGFR protein
expression and increased EGFR gene copy number are
associated with decreased survival [7–12], resistance to
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Fig. 1 Epidermal growth factor receptor and ErbB family down-
stream signaling pathways potentially involved in squamous cell
carcinomas of the head and neck. Downstream pathways activated by
dimerization and activation of the ErbB family. Adapted with
permission from Venook et al. [5]. 2005 John Wiley & Sons, Inc.
Akt v-akt murine thymoma viral oncogene homolog, serine-threonine
kinase 1, Bad Bcl-2 antagonist of cell death, Bcl B-cell lymphoma,
CdK cyclin dependent kinase, EGFR epidermal growth factor
receptor, ELK-1 Ets like gene 1, ErbB erythroblastic leukemia viral
oncogene homolog, ERK extracellular signal-regulated kinase, Fos
protooncogene c-fos, GRB2 growth factor receptor-bound protein 2,
HIF-1a hypoxia inducible factor-1a, JAK Janus kinase, MEK
mitogen-activated protein kinase kinase, mTOR mammalian target
of rapamycin, NF-jB nuclear factor-jB, PI3K phosphatidylinositol-3-
kinase, Raf v-raf 1 murine leukemia viral oncogene homolog 1, Ras
retrovirus-associated DNA sequences, SoS son of sevenless, STAT
signal transducers and activators of transcription, VEGF vascular
endothelial growth factor
2482 Med Oncol (2012) 29:2481–2491
123
radiotherapy [13], locoregional treatment failure [7–9], and
increased rates of distant metastases [8, 14].
Cetuximab (Erbitux, Bristol-Myers Squibb; New York,
NY, USA), a recombinant chimeric anti-EGFR monoclonal
antibody (mAb), was the first molecularly targeted therapy
approved for SCCHN. Cetuximab is approved in combi-
nation with radiation therapy for locally advanced disease,
in combination with platinum-based chemotherapy and
5-fluorouracil (5-FU) for the first-line treatment of meta-
static/recurrent disease, and as a single agent for meta-
static/recurrent disease after failure of platinum-based
chemotherapy [15]. This article will briefly review the
clinical trial data associated with cetuximab in SCCHN,
describe limitations of current therapy, and discuss data
associated with investigational EGFR- and ErbB family
targeted treatment strategies for SCCHN.
Cetuximab: proof of concept of EGFR inhibition
in locally advanced or metastatic SCCHN
Results from several clinical trials have established the
activity of cetuximab in the treatment of SCCHN.
A landmark phase III study involving 424 patients with
locoregionally advanced SCCHN compared cetuximab in
combination with high-dose radiotherapy versus high-dose
radiotherapy alone [16]. The combination of cetuximab
and radiotherapy significantly improved median overall
survival (OS; 49.0 vs. 29.3 months; hazard ratio [HR],
0.74; 95% confidence interval [CI], 0.57–0.97; P = 0.03)
and median progression-free survival (PFS; 17.1 vs.
12.4 months; HR, 0.70; 95% CI, 0.54–0.90; P = 0.006)
versus radiotherapy alone. The three most common adverse
events (AEs; C10% of patients) were mucositis (93% for
cetuximab/radiotherapy vs. 94% for radiotherapy alone),
radiation dermatitis (86% vs. 90%), and acneiform rash
(87% vs. 10%). The incidence of grade C3 AEs was also
similar between groups, with the exception of acneiform
rash (17% with cetuximab/radiation vs. 1% with radiation
alone; P \ 0.001) and infusion-related events (3% vs. 0%;
P = 0.01) [16]. Notably, incidence of radiation-associated
acute toxicities was not increased in combination with
cetuximab. Five-year survival rates were 45.6% for
cetuximab/radiation versus 36.4% for radiation alone (HR,
0.73; 95% CI, 0.56–0.95; P = 0.018) [17]. Preliminary
results from the phase III RTOG 0522 trial (N = 940)
evaluating concurrent accelerated radiation/cisplatin with
or without cetuximab demonstrated no significant
improvement with cetuximab in PFS (HR, 1.05; 95% CI,
0.84–1.29; P = 0.66), OS (HR, 0.87; 95% CI, 0.66–1.15;
P = 0.17), or total grade C3 AEs (92% vs. 90%;
P = 0.30). Higher rates of grade 3–4 mucositis (45% vs.
35%; P = 0.003) and skin reactions (40% vs. 17%;
P \ 0.0001) were observed in the cetuximab arm [18].
Cetuximab has also been evaluated in phase II studies in
combination with cisplatin and radiation in patients with
locally advanced SCCHN [19, 20].
In a number of ongoing phase III studies, cetuximab is
being evaluated in patients with locally advanced SCCHN.
Induction chemotherapy with docetaxel/cisplatin/5-FU
(TPF) followed by cisplatin/radiotherapy versus cetuximab/
radiotherapy (NCT00716391); cetuximab/radiotherapy
versus cisplatin/radiotherapy (NCT00999700); and cetux-
imab/radiotherapy versus carboplatin/5-FU/radiotherapy
(NCT01233843) is also being investigated. Another phase
III trial is evaluating TPF followed by radiotherapy plus
either concomitant chemotherapy or concomitant cetux-
imab versus radiotherapy plus either concomitant chemo-
therapy or concomitant cetuximab, without induction TPF
(NCT01086826).
Several clinical trials have evaluated cetuximab in the
metastatic/recurrent SCCHN setting. In the phase III E5397
trial (N = 117), first-line treatment with cisplatin plus
cetuximab significantly improved response rate (RR) versus
cisplatin alone (26% vs. 10%; P = 0.03) [21]. However, this
regimen did not demonstrate a significant effect on median
PFS (4.2 vs. 2.7 months; P = 0.09) or median OS (9.2 vs.
8 months; P = 0.21). The three most common grade 3–4
AEs (C10% of patients) were fatigue (17% for cetuximab
plus cisplatin vs. 14% for cisplatin alone), nausea (24% vs.
19%), and vomiting (17% in each arm). In another phase III
trial (EXTREME; N = 442), patients with previously
untreated metastatic/recurrent SCCHN were assigned ran-
domly to receive cisplatin or carboplatin plus 5-FU and
cetuximab or chemotherapy (platinum plus 5-FU) alone
[22]. The addition of cetuximab to chemotherapy signifi-
cantly increased median OS (10.1 vs. 7.4 months; HR, 0.80;
95% CI, 0.64–0.99; P = 0.04), median PFS (5.6 vs.
3.3 months; HR, 0.54; 95% CI, 0.43–0.67; P \ 0.001), and
RR (36% vs. 20%; odds ratio [OR], 2.33; 95% CI,
1.50–3.60; P \ 0.001) versus chemotherapy alone. The
three most frequently reported grade 3–4 AEs (C10% of
patients) were neutropenia (22% for chemotherapy/cetux-
imab vs. 23% for chemotherapy alone), anemia (13% vs.
19%), and thrombocytopenia (11% vs. 11%) [22]. A sepa-
rate phase II study evaluated cetuximab in combination with
carboplatin/paclitaxel as first-line therapy in patients who
had previously received induction or adjuvant platinum-
based chemotherapy (N = 33) [23]. The RR was 46%,
median OS was 10.3 months.
Two phase II studies demonstrated the efficacy of
cetuximab in combination with platinum-based chemo-
therapy as second-line treatment in patients with meta-
static/recurrent SCCHN who failed to respond to first-line
platinum-based chemotherapy alone [24, 25]. Reported
RRs and median OS were approximately 10% and
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5–6 months, respectively, and the most common AEs were
anemia, rash, asthenia, and nausea/vomiting. In another
phase II trial in patients with metastatic/recurrent SCCHN
refractory to platinum-based chemotherapy (N = 103),
cetuximab monotherapy was associated with a RR of 13%
and median OS of 178 days [26]. Similar to other trials, the
most common AEs were rash, acne, and asthenia.
In general, AEs associated with cetuximab are mild to
moderate and clinically manageable [27]; the most com-
mon toxicity associated with cetuximab therapy is an acne-
like pustular rash, which is observed in [70% of patients
[16, 21, 24]. In some studies, an association between the
presence of rash and improved OS has been proposed [17,
21, 24]. Hypomagnesemia may also occur following
cetuximab therapy (reported in 5–14% of patients) [21, 22],
due to inhibition of magnesium reabsorption within the
kidney secondary to EGFR blockade [27, 28]. Patients
therefore require routine monitoring during treatment.
Grade 4 infusion-related reactions have also been reported
in a minority (*3%) of patients [17, 21, 27, 28].
Limitations of current treatment options for locally
advanced or metastatic SCCHN
The current standard of care for locally advanced SCCHN
may consist of surgery, chemoradiotherapy, and/or cetux-
imab therapy [3]. Although developments in radiotherapy
and surgical and imaging techniques have improved patient
function following intervention (e.g., preservation of
associated and adjacent organs and structures) [29–31], OS
has increased only modestly. In addition, current treat-
ments may be associated with both acute and chronic
adverse effects [29, 30]. A meta-analysis of clinical trial
data from [17,000 SCCHN patients treated with curative
intent showed that concomitant chemotherapy and radio-
therapy was associated with an absolute 5-year survival
benefit of 6.5% (over radiotherapy alone) compared with
2.4% for induction chemotherapy followed by radiotherapy
versus radiotherapy alone [30]. In the previously men-
tioned landmark phase III trial in patients with locally
advanced SCCHN that compared cetuximab in combina-
tion with high-dose radiotherapy versus high-dose radio-
therapy alone, the 5-year survival benefit with the addition
of cetuximab to radiotherapy was approximately 9% versus
radiotherapy alone [17]. While this compares favorably to
the 6.5% increase observed with the addition of platinum-
based chemotherapy to radiotherapy [30], these results
should be interpreted with caution as the study did not
compare the cetuximab combination with platinum-based
chemoradiotherapy [28].
For metastatic/recurrent SCCHN, the current standard of
care is chemotherapy, particularly platinum-based agents
with or without addition of 5-FU, with the goals of palli-
ation of symptoms and prolongation of OS. In addition,
cetuximab is currently approved as a treatment option for
recurrent or metastatic SCCHN as first-line therapy in
combination with platinum-based chemotherapy or for
patients progressing after platinum-based therapy [15]. The
use of combination chemotherapy in metastatic/recurrent
SCCHN is based on improvement in response observed
with combination chemotherapy versus single-agent che-
motherapy in randomized trials [32, 33]; however, no
significant extension in OS was observed. No specific
doublet regimen has demonstrated improved efficacy over
others to date [32, 34] (Fig. 2a), and a variety may be
utilized in clinical practice [29]. The addition of a third
cytotoxic agent in this patient population may improve
a
b
Fig. 2 Survival estimates from key trials of chemotherapy in patients
with SCCHN. Kaplan–Meier estimates of overall survival in patients
with metastatic/recurrent SCCHN treated with (a) methotrexate
versus cisplatin/5-fluorouracil versus carboplatin/5-fluorouracil
(Southwest Oncology Group) [32]; b cetuximab plus 5-fluorouracil/
platinum-based chemotherapy versus 5-fluorouracil/platinum-based
chemotherapy alone (NCT00122460) [22]. a Reprinted with permis-
sion [32] 1992 American Society of Clinical Oncology. All rights
reserved. b Reprinted with permission [22] 2008 Massachusetts
Medical Society. SCCHN squamous cell carcinoma of the head and
neck, 5-FU 5-fluorouracil
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outcomes in some cases, but this option is generally limited
by increased toxicity [35–37]. The EXTREME trial was the
first study in over 25 years to demonstrate a survival
advantage in the metastatic/recurrent SCCHN setting, with
significant improvements for cetuximab plus 5-FU and
platinum-based chemotherapy versus chemotherapy alone
(Fig. 2b) [22]. However, the issues of treatment sequence,
potential cross-resistance, synergy, and whether the added
benefit of cetuximab would be maintained if given after
chemotherapy upon disease progression were not addressed
[28].
Despite therapeutic advances, the 5-year survival rate
for head and neck cancers in the US has remained
approximately 55–65% since the mid-1970s [28, 38]. Both
radiotherapy and chemotherapeutic approaches may have
been optimized in terms of balancing efficacy and safety/
tolerability [4], and the use of higher doses of chemo-
therapy in an attempt to overcome resistance has generally
resulted in unacceptable toxicity and damage to healthy
adjacent tissues [28]. While cetuximab has demonstrated
activity in SCCHN, new agents and treatment strategies are
needed that will provide both improved tolerability and
efficacy.
Future directions beyond cetuximab: inhibiting
the ErbB family
Several novel agents targeting the ErbB/HER receptor
family are being evaluated in phase II and III clinical trials
for the treatment of SCCHN (Table 1).
Anti-EGFR monoclonal antibodies
Panitumumab (Vectibix, Amgen; Thousand Oaks, CA,
USA) is a fully human anti-EGFR mAb. In a phase I study,
the combination of panitumumab with carboplatin, paclit-
axel, and intensity-modulated radiotherapy was evaluated
in patients with locally advanced SCCHN (N = 19) [39].
All patients achieved at least a partial response (PR), and
the most common AEs (C10% of patients) were oral pain,
xerostomia, acneiform rash, and anemia. The phase II
PRISM study evaluated second-line panitumumab mono-
therapy following prior chemotherapy for metastatic/
recurrent SCCHN (N = 52) [40]. The interim safety anal-
ysis demonstrated that the most common AEs (C10% of
patients) were skin disorders, fatigue, hypomagnesemia,
and nausea. Grade C 3 skin-related AEs were observed in
12% of patients. In SPECTRUM, cisplatin/5-FU plus
panitumumab was compared with cisplatin/5-FU alone in
patients with metastatic/recurrent SCCHN (N = 657) [41].
The addition of panitumumab to chemotherapy did not
significantly improve median OS versus chemotherapy
alone (11.1 vs. 9.0 months; HR, 0.87; 95% CI, 0.73–1.05;
P = 0.14), but did improve median PFS (5.8 vs.
4.6 months; HR, 0.78; 95% CI, 0.66–0.92; P = 0.004).
The RR was 36% for panitumumab plus chemotherapy
versus 25% for chemotherapy alone. The three most
common grade C3 AEs (C10% of patients) were neutro-
penia (32% for panitumumab and chemotherapy vs. 33%
for chemotherapy alone), skin toxicity (17% vs. 1%), and
anemia (12% vs. 14%). Infusion-related reactions of any
grade occurred in \1% of patients in each group [41].
Several ongoing phase II studies are currently evaluating
panitumumab in locally advanced SCCHN (combination
with radiotherapy vs. chemoradiotherapy, NCT00547157;
combination with chemoradiotherapy, NCT00500760;
combination with postoperative chemoradiotherapy,
NCT00798655) or metastatic/recurrent SCCHN (as first-line
treatment in combination with cisplatin and docetaxel,
NCT00454779). An ongoing phase III trial is evaluating
panitumumab plus radiotherapy versus cisplatin plus radio-
therapy for locally advanced SCCHN (NCT00820248).
Nimotuzumab (YM Biosciences; Ontario, Canada) is a
humanized anti-EGFR mAb that has been granted approval
in SCCHN in several countries outside the United States. It
exhibits a reduced binding affinity for the EGFR compared
with the murine mAb [42], but has demonstrated a unique
clinical profile, with an absence of the severe skin toxici-
ties that are observed with cetuximab and panitumumab.
Table 1 ErbB family inhibitors
in phase II and III studies for the
treatment of squamous cell
carcinoma of the head and neck
EGFR epidermal growth factor
receptor, IV intravenous, mAb
monoclonal antibody, PO oral,
TKI tyrosine kinase inhibitor
Agent Mechanism/target/binding Method of
administration
Panitumumab Fully human anti-EGFR mAb IV
Nimotuzumab Humanized anti-EGFR mAb IV
Zalutumumab Fully human anti-EGFR mAb IV
Gefitinib Reversible, small-molecule EGFR TKI PO
Erlotinib Reversible, small-molecule EGFR TKI PO
Lapatinib Reversible, small-molecule EGFR/ErbB2 TKI PO
Afatinib (BIBW 2992) Irreversible, small-molecule ErbB family inhibitor PO
PF-00299804 Irreversible, small-molecule pan-HER TKI PO
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A pharmacodynamic study assessing the combination of
nimotuzumab and radiotherapy in patients with unresec-
table locoregional SCCHN showed that nimotuzumab was
well tolerated, with no evidence of skin rash. Nine of 10
patients achieved an objective response based on RECIST
criteria [43].
In a phase I/II trial, nimotuzumab plus radiotherapy was
evaluated in 24 patients with locally advanced SCCHN
[44]. The RR was 50% with doses of 50–100 mg (low
dose) nimotuzumab, and 81% with 200–400 mg (high
dose) nimotuzumab. Median OS for low-dose nim-
otuzumab was 8.6 months, compared with 44.3 months for
high-dose nimotuzumab (P = 0.03 for high- vs. low dose).
Three-year OS rates were 16.7 and 66.7% for the low- and
high doses, respectively. The most common AEs with high-
dose nimotuzumab were fever, hypotension, and tremors.
No cases of skin rash were observed [44]. A separate phase
IIb study investigated nimotuzumab plus chemoradiother-
apy versus chemoradiotherapy alone (group 1), or nim-
otuzumab plus radiotherapy versus radiotherapy alone
(group 2), as first-line therapy in 92 patients with advanced
unresectable SCCHN [45]. The RR (100% vs. 70%;
P = 0.02), median PFS (not reached vs. 12.66 months;
P = 0.013), and median OS (not reached vs. 22.0 months;
P = 0.004) were all significantly improved with nim-
otuzumab plus chemoradiotherapy versus chemoradio-
therapy alone. With nimotuzumab plus radiotherapy, the
RR was 76% versus 40% for radiotherapy alone
(P = 0.023), while median PFS was 10.1 versus
6.9 months (P = 0.24), and median OS was 14.37 versus
12.79 months (P = 0.71), respectively. The nimotuzumab-
related AEs in group 1 were asthenia, dizziness, micro-
scopic hematuria, vomiting, and loose stools; fever, chills,
pruritus, rash, headache, hypertension, and fluctuation in
blood pressure were reported as nimotuzumab-related AEs
in group 2. There were four cases of skin reactions in
patients receiving nimotuzumab [45]. At 48 months, the
addition of nimotuzumab to chemoradiotherapy signifi-
cantly increased median OS compared with chemoradio-
therapy alone (47% vs. 21%; HR, 0.35; P = 0.01), but not
when combined with radiotherapy versus radiotherapy
alone (34% vs. 13%; P = not specified) [46].
In a double-blind trial, patients with unresectable loco-
regional SCCHN (N = 106) were assigned randomly to
receive first-line therapy with nimotuzumab plus radio-
therapy versus placebo plus radiotherapy [47]. Complete
RRs were 59.5% for patients receiving nimotuzumab and
radiotherapy versus 34.2% of patients receiving radio-
therapy alone (P = 0.038), and median OS was
12.5 months and 9.5 months (P = 0.0491), respectively. In
a subgroup analysis of patients with EGFR-positive
tumors, significant survival benefit was seen with nim-
otuzumab plus radiotherapy versus radiotherapy alone
(16.5 vs. 7.2 months; P = 0.0038). The three most com-
mon AEs considered to be related to nimotuzumab treat-
ment were asthenia, fever, and headache. No cases of skin
rash were observed. A small pilot study involving 17
patients with locally advanced SCCHN was conducted to
evaluate the combination of nimotuzumab and concurrent
chemotherapy [48]. The RR was 76% and no grade 3–4
AEs were reported. An ongoing phase II study is being
conducted to investigate the combination of nimotuzumab
plus cisplatin and radiotherapy for locally advanced
SCCHN (NCT00702481), and a phase III study is assessing
postoperative concurrent chemoradiotherapy with or
without nimotuzumab for locally advanced SCCHN
(NCT00957086).
Zalutumumab (Genmab; Copenhagen, Denmark) is a
fully human, high-affinity anti-EGFR mAb [49], which has
received fast track designation from the Food and Drug
Administration for advanced, metastatic, and/or unresec-
table SCCHN that has progressed following standard
platinum-based chemotherapy. In a phase I/II study in 28
patients with metastatic/recurrent SCCHN, zalutumumab
was associated with a RR of 7.1% [50]. The most fre-
quently reported AEs were infusion-related reactions,
rash/acne, and dyspnea. In a phase III pivotal trial,
zalutumumab plus best supportive care (BSC) was com-
pared with BSC plus optional methotrexate (control group)
in 286 patients with metastatic/recurrent SCCHN after
failure of platinum-based chemotherapy [51]. The dose of
zalutumumab was titrated according to the development of
skin rash in individual patients. Median OS was not sig-
nificantly different between groups (6.7 vs. 5.2 months in
the zalutumumab versus control group, respectively; HR,
0.77; 95% CI, 0.57–1.05; P = 0.0648), but PFS was sig-
nificantly prolonged (9.9 vs. 8.4 weeks; HR, 0.63; 95% CI,
0.47–0.84; P = 0.0012). The three most common AEs
(C10% of patients) were rash (92% for zalutumumab and
BSC versus 0% for control), anemia (25% vs. 19%), and
pyrexia (22% vs. 13%). Grade 3–4 AEs that were more
common in the zalutumumab group than in the control
group included rash, hypomagnesemia, pneumonia, and
headache. Results are awaited from a phase I/II trial of
zalutumumab plus cisplatin-based chemoradiotherapy
as first-line therapy for locally advanced SCCHN
(NCT00401401). A phase III study to determine whether
the addition of zalutumumab to primary curative radio-
therapy increases locoregional control in SCCHN is cur-
rently recruiting patients (DAHANCA 19, NCT00496652).
Tyrosine kinase inhibitors (TKIs) targeting EGFR
Gefitinib (Iressa, AstraZeneca; Wilmington, DE), an oral,
small-molecule, reversible EGFR TKI, was the first TKI to
reach phase III investigation in SCCHN, but is no longer
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being pursued for this indication due to recent negative
study results [4]. In a phase II trial assessing second-line
gefitinib 500 mg/day in patients with metastatic/recurrent
SCCHN (N = 52), the RR was 10.6%, median OS was
8.1 months, and 1-year OS rate was 29.2% [52]. The most
common AEs were diarrhea, skin toxicity, and anorexia.
A subsequent phase II trial was conducted to evaluate
gefitinib 250 mg/day in patients with recurrent and/or
metastatic SCCHN (N = 71), with the aim of reducing the
incidence of toxicities [53]. One patient achieved a PR.
Median OS was 5.5 months and PFS was 1.8 months,
while the 1-year OS rate was estimated at 19%. Skin tox-
icity was reported for 64% of patients.
When gefitinib 250 mg/day was combined with radio-
therapy in a phase I/II study involving 16 patients with
locally advanced inoperable SCCHN, the RR was 37.5%
[54]. Neoadjuvant gefitinib in combination with docetaxel,
carboplatin, and 5-FU, followed by concurrent docetaxel,
radiation therapy, and gefitinib was evaluated in patients
with locally advanced SCCHN (N = 62) [55]. Following
completion of neoadjuvant therapy, the RR was 46%, and
following completion of adjuvant therapy, the RR was 80%.
The estimated 3-year survival rate was 54%. The most
common grade 3–4 AEs reported during the neoadjuvant
treatment phase were neutropenia, oral mucositis, and
diarrhea, while during the adjuvant phase, these were oral
mucositis/esophagitis/dysphagia, anorexia, and fatigue.
Two phase III studies have assessed gefitinib in patients
with metastatic/recurrent SCCHN. In patients who had
received numerous prior treatments, gefitinib 250 mg/day
plus docetaxel was compared with docetaxel alone
(N = 270) [56]. The study was terminated early, with a
reported median OS of 6.8 months for gefitinib plus doce-
taxel versus 6.0 months for docetaxel alone (P = 0.74);
median PFS was 3.3 versus 2.2 months (P = 0.18). In a
separate trial, gefitinib 250 mg/day, gefitinib 500 mg/day,
and methotrexate were compared in 486 patients [57].
Neither dose of gefitinib significantly increased median OS
compared with methotrexate (gefitinib 250 mg/day,
5.6 months vs. methotrexate, 6.0 months; HR, 1.22; 95% CI,
0.95–1.57; P = 0.12; and gefitinib 500 mg/day, 6.7 months
vs. methotrexate, 6.0 months; HR, 1.12; 95% CI, 0.87–1.43;
P = 0.39). The RR was 2.7% for gefitinib 250 mg/day,
7.6% for gefitinib 500 mg/day, and 3.9% for methotrexate,
with no significant differences between either dose of gefi-
tinib and methotrexate. The three most common AEs (C10%
of patients) with gefitinib 250 mg/day, gefitinib 500 mg/
day, and methotrexate were rash (29.1, 39.2, and 4.4%),
diarrhea (25.9, 39.2, and 11.9%), and stomatitis (9.5, 13.9,
and 34.6%).
Erlotinib (Tarceva, Genentech; South San Francisco,
CA) is another oral, small-molecule, reversible EGFR TKI
that has demonstrated efficacy in patients with SCCHN. In
a phase I/II study involving 37 patients with locally
advanced SCCHN, erlotinib administered in combination
with cisplatin and radiotherapy was associated with a RR
of 74% (all complete responses [CRs]) and 3-year PFS and
OS rates of 61 and 72%, respectively [58]. The most
common nonhematologic AEs were nausea/vomiting,
dysphagia, and stomatitis. In another phase II study,
patients with locally advanced SCCHN (N = 128) were
assigned randomly to receive cisplatin plus radiotherapy or
cisplatin plus radiotherapy and erlotinib [59]. An interim
analysis of the first 100 patients demonstrated a RR for
both treatment arms of 71% (all CR), and the most com-
mon serious AEs were nausea, vomiting, and dehydration.
Erlotinib monotherapy was evaluated in a phase II trial
involving 155 patients with metastatic/recurrent SCCHN
[60]. The RR was 4.3%, median OS was 6.0 months, and
median PFS was 9.6 weeks. The most common drug-
related AEs were rash, diarrhea, and dry skin. A separate
phase I/II study was conducted to evaluate erlotinib plus
cisplatin in patients with metastatic/recurrent SCCHN
(N = 51) [61]. Of 43 evaluable patients, nine demonstrated
a tumor response, the median PFS was 3.3 months, and the
median OS was 7.9 months. The three most frequently
reported AEs were rash, hypomagnesemia, and anemia.
In ongoing phase II studies, erlotinib in combination with
cisplatin-based chemotherapy is being evaluated in chemo-
naive metastatic/recurrent SCCHN (NCT01064479,
NCT00076310); as first-line therapy in combination with
cetuximab, carboplatin, and paclitaxel for metastatic/recur-
rent SCCHN (NCT01316757); as first-line therapy in com-
bination with chemoradiotherapy for locally advanced
SCCHN (NCT00720304; NCT00442455); and as first-line
therapy in combination with radiotherapy for locally
advanced SCCHN (NCT01192815). Phase III studies of erl-
otinib in combination with first-line platinum-based chemo-
therapy for metastatic/recurrent SCCHN (NCT00448240)
and as maintenance therapy in fully resected SCCHN
(NCT00412217) were terminated due to low enrollment.
Lapatinib (Tykerb, GlaxoSmithKline; Research Tri-
angle Park, NC, USA) is an oral, small-molecule, revers-
ible inhibitor of both EGFR and ErbB2/HER2 [62]. In a
phase I dose-escalation study involving 31 patients with
locally advanced SCCHN, lapatinib was administered in
combination with cisplatin and radiotherapy [63]. The RR
was 81% for all doses combined (500, 1,000, and
1,500 mg/day) and 65% at the recommended phase II dose
of 1,500 mg/day. The most common AEs (C10% of
patients) at 1,500 mg/day were radiation mucositis, radia-
tion dermatitis, nausea, and vomiting. In a subsequent
phase II trial, lapatinib was again combined with cis-
platin and radiotherapy, followed by maintenance lapati-
nib or placebo, after completion of chemoradiotherapy
in patients with locally advanced SCCHN (N = 67) [64].
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The complete RR was 53% with lapatinib versus 36% with
placebo, and HRs for PFS and OS were 0.71 (95% CI,
0.34–1.52) and 0.70 (95% CI, 0.31–1.63), respectively. No
grade 3–4 AEs were observed during maintenance therapy,
other than grade 3 localized edema (lapatinib, 3%) and
weight loss (placebo, 3%).
In a separate phase II study of lapatinib monotherapy in
patients with metastatic/recurrent SCCHN (N = 42), no
objective responses were observed [65]. In ongoing phase
II studies, lapatinib plus capecitabine is being evaluated in
metastatic/recurrent SCCHN (NCT01044433), and lapati-
nib plus radiotherapy is being evaluated in patients with
locally advanced SCCHN who cannot tolerate chemother-
apy (NCT00490061). In addition, a phase III study is being
conducted to investigate lapatinib versus placebo admin-
istered postoperatively in combination with chemoradio-
therapy followed by maintenance lapatinib/placebo in
high-risk patients (NCT00424255).
A key limitation of currently available EGFR-targeted
therapies, including mAbs and TKIs, is de novo or acquired
resistance, mediated through mechanisms including the
mutant type III variant of EGFR [66, 67], mutations in the
tyrosine kinase domain of EGFR [67], and tumor cell
surface expression of other members of the ErbB receptor
family [68]. In an effort to address this issue, TKIs that
block more than one member of the ErbB family and/or
bind irreversibly to their targets are being investigated for
the treatment of SCCHN.
Afatinib (BIBW 2992, Boehringer Ingelheim; Ingel-
heim, Germany) is an oral, small-molecule, irreversible
ErbB family inhibitor that targets EGFR, ErbB2, and
ErbB4 [69, 70]. Preliminary results from stage 1 of a
2-stage phase II study of afatinib versus cetuximab in 124
patients with platinum-refractory metastatic/recurrent
SCCHN showed PRs in 22 and 13% of patients, respec-
tively [71]. Median PFS was 16 versus 10 weeks for
afatinib versus cetuximab, respectively. Primary afatinib-
related AEs were diarrhea and skin-related AEs, while
skin-related AEs were the primary cetuximab-related AEs.
A phase III trial of afatinib versus methotrexate in patients
with platinum-refractory metastatic/recurrent SCCHN
(NCT01345682) is planned, and a phase III trial of afatinib
versus placebo as adjuvant therapy after chemoradiother-
apy in patients with unresected locoregional SCCHN
(NCT01345669) is recruiting participants.
PF-00299804 (PF-299, Pfizer; New York, NY, USA) is
an oral, small-molecule, irreversible, pan-HER inhibitor
that targets EGFR, ErbB2, and ErbB4 [72]. Results from
the first stage of a 2-stage phase II study investigating PF-
00299804 as first-line treatment in metastatic/recurrent
SCCHN showed PRs in 6 of 56 (11%) evaluable patients,
and median PFS of 2.8 months. The most common grade 3
AEs (C3% of patients) were diarrhea, fatigue, dermatitis
acneiform, and hand–foot skin reaction [73]. The criteria
for proceeding to stage 2 of the trial were fulfilled and
patient accrual is ongoing.
In addition to treatment strategies targeting more than one
ErbB receptor family member and/or binding irreversibly,
approaches that combine agents with different mechanisms of
action, i.e., targeting other pathways involved in SCCHN, may
also have potential to delay or overcome resistance to EGFR-
targeted therapy in SCCHN [67]. Preclinical data support the
evaluation of the mammalian target of rapamycin (mTOR)
pathway, which is involved in EGFR downstream signaling,
as a potential therapeutic strategy for SCCHN [74, 75].
A number of clinical trials are currently investigating such
treatment combinations. Two phase II studies are evaluating
erlotinib plus temsirolimus (NCT01009203) or everolimus
(NCT00942734) in platinum-refractory SCCHN. Cetuximab
plus temsirolimus is being evaluated in a phase II study in
patients with metastatic/recurrent SCCHN not responding to
prior cetuximab-based therapy (NCT01256385). Other phase
I/II studies are evaluating cetuximab plus platinum and ever-
olimus (NCT01283334), or temsirolimus (NCT01015664), in
metastatic/recurrent SCCHN. Cetuximab with cisplatin/pac-
litaxel plus everolimus or placebo is also being investigated in
a phase II study in locally advanced SCCHN (NCT01133678).
High levels of vascular endothelial growth factor (VEGF)
expression and some subtypes of VEGF receptors (VEGFRs)
[76, 77] that are associated with tumor angiogenesis, lym-
phangiogenesis, and an increased risk of mortality have been
observed in SCCHN tumors [76–78]. Results from a phase
I/II study of erlotinib plus the anti-VEGFR mAb bev-
acizumab in patients with metastatic/recurrent SCCHN
(N = 48) demonstrated an RR of 15%, a median PFS of
4.1 months, and a median OS of 7.1 months [79]. The most
common AEs (C10% of patients) were rash, diarrhea, and
fatigue. Ongoing phase II studies are evaluating erlotinib
plus bevacizumab (NCT00392665) or cetuximab plus
bevacizumab (NCT00409565, NCT00407810) in patients
with metastatic/recurrent SCCHN, and cetuximab with
bevacizumab plus chemoradiotherapy (NCT00703976,
NCT00968435) for locally advanced SCCHN. Sorafenib, an
inhibitor of multiple protein kinases, including those associ-
ated with VEGFRs, is also being evaluated in a phase II study
for SCCHN in combination with cetuximab (NCT00815295).
Conclusions
While several advances have been made in recent decades
related to the treatment of locally advanced and metastatic
SCCHN, the modest improvements in survival indicate that
new treatment strategies are needed. The accumulating
data with cetuximab validate the use of anti-EGFR-targeted
therapy in this patient group. Several EGFR-targeted
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treatment strategies beyond cetuximab are also being
evaluated in phase II and phase III clinical studies for
SCCHN, and results from large ongoing clinical trials are
awaited. As results of clinical studies mature, greater
insight into the potential placement of these agents into the
treatment paradigm in SCCHN may be revealed. Validated
biomarkers with the potential to predict treatment activity
and/or resistance may also contribute to improved patient
outcomes in SCCHN.
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